stockrowBioXcel Therapeutics, Inc.
BTAIQ Healthcare Drug Manufacturers Specialty & Generic
BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024.
- Revenue
- +51.7%
- EPS
- +80.0%
- Free cash flow
- +51.5%
- Total debt
- −3.90%
Quarter to June 2026, against a year earlier
Follow BTAIQ
Alert me
BioXcel Therapeutics, Inc. (BTAIQ) EV/Sales
As of 5 November 2026, BioXcel Therapeutics, Inc. (BTAIQ) trades at a EV/Sales of 228×. Over the past ten years it has ranged from 0.0× (June 2023) to 304× (July 2023); the current reading is higher than 95% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 156× | 301.88% |
| FY2024 | 38.9× | (55.66%) |
| FY2023 | 87.7× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 285× | 68.78% |
| Mar 2026 | 169× | 7.89% |
| Dec 2025 | 156× | 8.71% |
| Sep 2025 | 144× | 19.68% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. compare | −5.9× |
| SBFM Sunshine Biopharma, Inc. compare | −0.3× |
| IMCC IM Cannabis Corp. compare | 0.0× |
| AKAN Akanda Corp. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| YCBD cbdMD, Inc. compare | 0.2× |
| RDHL Redhill Biopharma Ltd. compare | 6.4× |
| BTAIQ BioXcel Therapeutics, Inc. | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)